Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,848 total articles
NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, will release its first quarter 2026 financial results on May 12, 2026, prior to market open. The company will also host a conference call to discuss the results and business update. NeurAxis focuses on the commercialization of its proprietary PENFS technology, I…
Relmada Therapeutics announced presentations of two abstracts related to NDV-01, their sustained-release gemcitabine-docetaxel formulation for non-muscle invasive bladder cancer (NMIBC), at the American Urology Association 2026 event. Phase 2 data in high-risk NMIBC patients showing 9-12 month efficacy results will be presented, alongside a Phase 3…
Arvinas, a biotechnology company specializing in targeted protein degradation therapies, announced it will release its first quarter 2026 financial results on May 12, 2026, accompanied by a corporate update webcast. The company continues advancing multiple clinical-stage investigational drugs, including FDA-approved VEPPANU developed with Pfizer fo…
EVgo Inc. announced strong first quarter 2026 financial results, achieving record revenues of $110 million, a 45% increase year-over-year. The company expanded its public fast charging stalls by 25% to 5,280 and grew network throughput by 10%, reinforcing its leadership in the U.S. EV charging market. Key strategic initiatives include scaling the n…
Ocular Therapeutix announced its first quarter 2026 financial results along with significant clinical progress in its AXPAXLI program for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Key highlights include positive Phase 3 SOL-1 trial results demonstrating superiority over existing anti-VEGF treatment, initiation of the …
Eupraxia Pharmaceuticals reported encouraging EREFS (Endoscopic Reference Score) data from the ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data show that a higher number of esophageal wall injections (20 injections) resulted in significant improvement in inflammation and fibrosis scores, supporting …
NRx Pharmaceuticals initiated commercial manufacturing of its preservative-free ketamine product utilizing an innovative blow-fill-seal process at a US-based facility. The product aims to address ongoing supply shortages in sterile intravenous ketamine, with production capacity supporting significant sales and scalability. This new formulation excl…
Rhythm Pharmaceuticals announced first quarter 2026 financial results featuring $60.1 million in global net product revenue for IMCIVREE, a treatment for acquired hypothalamic obesity (HO) and rare genetic obesity disorders. The company reported a successful U.S. launch post FDA approval, received European Commission authorization expanding indicat…
Fractyl Health, a clinical stage metabolic therapeutics company focused on innovative treatments for obesity and type 2 diabetes, will announce its Q1 2026 financial results and provide business updates on May 12, 2026. Additionally, CEO Dr. Harith Rajagopalan will present at the BofA Securities 2026 Health Care Conference on May 14, 2026.
Climb Bio announces significant progress in the development of budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated immune diseases. Positive topline Phase 1 data shows robust B-cell depletion via a subcutaneous formulation, supporting advancement to patient trials. Clinical trials for primary membranous nephropathy, immune thromb…
Seres Therapeutics announced first quarter 2026 financial results showing a net loss of $19.9 million compared to net income in the prior year period, impacted by absence of payments from the 2024 VOWST sale. The company is nearing clinical data readout from an investigator-sponsored study of SER-155 for immune checkpoint inhibitor-related enteroco…
Sotera Health Company announced that Alton Shader, current CEO of Viant Medical, will become CEO and join the Board of Directors on May 26, 2026, succeeding Michael B. Petras, Jr. Petras will transition to Executive Chairman to support a smooth leadership change. Shader brings over 20 years of medical industry experience with a focus on growth and …
First Watch Restaurant Group, Inc. announced Q1 2026 financial results showing a 17.3% increase in total revenues to $331.0 million and 2.8% same-restaurant sales growth. Despite a net loss of $2.7 million, adjusted EBITDA rose to $27.8 million. The company opened 16 new restaurants and reaffirmed its full-year growth outlook while raising the low …
Shoals Technologies Group, a leading electrical infrastructure solutions provider for the energy transition market, reported Q1 2026 revenue of $140.6 million, a 74.9% increase year-over-year, driven by strong demand and market share gains. Despite a slight net loss of $0.3 million attributable to litigation settlement expenses, the company achieve…
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company developing oral antiviral therapies, announced it will hold a conference call and webcast on May 12, 2026, to discuss its financial results for the first quarter ended March 31, 2026, and to provide a business update. The company is advancing its pipeline with antiviral drugs targetin…
Cellectar Biosciences announced an oversubscribed financing round totaling up to $140 million led by Nantahala Capital and other healthcare-focused investors. The funds will support the confirmatory study and NDA filing for accelerated approval of iopofosine I 131 in WaldenstrF6m macroglobulinemia with the FDA and advance their PDC delivery platfor…
Editas Medicine announced positive first quarter 2026 results including significant advancements in its lead gene editing therapy candidate EDIT-401, which demonstrated over 90% LDL cholesterol reduction in preclinical studies. The company plans to initiate a first-in-human clinical trial by the end of 2026, with early proof-of-concept data expecte…
GLOBALFOUNDRIES reported Q1 2026 financial results showing revenue of $1.634 billion with solid profitability metrics exceeding guidance. The company launched its SCALE optical module for co-packaged optics and expanded a strategic partnership with Renesas Electronics, enhancing its presence in automotive and data center markets. GF also announced …
Autolus Therapeutics plc, a US-listed commercial stage biopharmaceutical company specializing in next-generation programmed T cell therapies, will release its Q1 2026 financial results on May 14, 2026, before US market open. The company will also host a conference call and webcast to discuss financial outcomes and provide a business update.
FactSet's Board of Directors announced an increase in the quarterly dividend from $1.10 to $1.16 per share, continuing its long-standing commitment to shareholder returns. This marks the 27th consecutive year of dividend increases on a stock split-adjusted basis, highlighting the company's strong financial performance and stability. The dividend wi…
Shopify announced its financial results for Q1 2026, highlighting a 34% year-over-year revenue growth and crossing $100 billion in Gross Merchandise Volume (GMV). The company maintained a 15% free cash flow margin and expects continued growth in Q2 2026 with high twenties percentage revenue increase. Shopify emphasizes its competitive edge by lever…
Regeneron Pharmaceuticals and Sanofi reported positive results from the REMODEL Phase 4 trial showing that Dupixent (dupilumab) significantly improves esophageal distensibility and reduces disease-related structural and inflammatory changes in adult patients with eosinophilic esophagitis (EoE). These findings reinforce Dupixent's role in treating t…
Tilray Brands' BrewDog has entered a 12-month partnership with Underbelly to become the official beer supplier at key UK venues and festivals such as Underbelly at the Edinburgh Fringe, Christmas in Trafalgar Square, and Underbelly Boulevard Soho. This partnership offers BrewDog expanded reach and visibility at major live entertainment events, enha…
Kymera Therapeutics reported new preclinical data demonstrating that KT-579, an oral IRF5 degrader, showed potent disease-modifying activity in inflammatory bowel disease models, performing comparably or better than current therapies. The ongoing Phase 1 trial in healthy volunteers is expected to yield data in the second half of 2026, supporting th…
Axsome Therapeutics, a biopharmaceutical company specializing in treatments for central nervous system disorders, will present at the BofA Securities 2026 Health Care Conference and RBC Capital Markets Global Healthcare Conference in May 2026. The company focuses on novel therapies addressing significant neurological and psychiatric conditions and …
